Last 12 months
Inside the activity.
2 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 9 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2022 Filed May 20, 2022 20:10 UTC |
Jackson Scott ThomasDirector
|
GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-22-030982 · doc4.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: The shares underlying this option vest on May 18, 2023, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:16 UTC |
King Rachel K.Director
|
GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-22-030999 · doc4.xml · derivative · entry 1 King Rachel K. · CIK 0001589712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: The shares underlying this option vest on May 18, 2023, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:08 UTC |
Goldberg Mark AlanDirector
|
GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-22-030977 · doc4.xml · derivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: The shares underlying this option vest on May 18, 2023, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 22:06 UTC |
Magnani John L.SVP of Research, CSO
|
SaleCommon Stock | 3,227 | $1.09 | $3,517.43 |
DisclosureSEC source: 0001209191-22-017977 · doc4.xml · nonDerivative · entry 1 Magnani John L. · CIK 0001589713 · SVP of Research, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,033 F1 · kind: The sales reported on this Form 4 were effected to satisfy tax withholding obligations in connection with the settlement of restricted stock units as part of a "sell to cover" transaction and do not represent discretionary trades by the reporting person. F2 · price: The common stock was sold by the reporting person in a series of open market transactions on the transaction date with a volume weighted average sale price of $1.09. The range of sales prices for the transactions reported was $1.09 to $1.10 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 22:05 UTC |
Girard ArmandSVP, Chief Business Officer
|
SaleCommon Stock | 2,339 | $1.09 | $2,549.51 |
DisclosureSEC source: 0001209191-22-017968 · doc4.xml · nonDerivative · entry 1 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,661 F1 · kind: The sales reported on this Form 4 were effected to satisfy tax withholding obligations in connection with the settlement of restricted stock units as part of a "sell to cover" transaction and do not represent discretionary trades by the reporting person. F2 · price: The common stock was sold by the reporting person in a series of open market transactions on the transaction date with a volume weighted average sale price of $1.09. The range of sales prices for the transactions reported was $1.09 to $1.11 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 22:03 UTC |
Hahn Brian M.SVP Finance, CFO
|
SaleCommon Stock | 2,917 | $1.09 | $3,179.53 |
DisclosureSEC source: 0001209191-22-017963 · doc4.xml · nonDerivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,843 F1 · kind: The sales reported on this Form 4 were effected to satisfy tax withholding obligations in connection with the settlement of restricted stock units as part of a "sell to cover" transaction and do not represent discretionary trades by the reporting person. F2 · price: The common stock was sold by the reporting person in a series of open market transactions on the transaction date with a volume weighted average sale price of $1.09. The range of sales prices for the transactions reported was $1.09 to $1.11 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2022 Filed Feb 6, 2023 21:13 UTC |
King Rachel K.Director
|
OtherCommon Stock | 11,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007267 · doc5.xml · nonDerivative · entry 1 King Rachel K. · CIK 0001589712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,955 F1 · balance_after: Includes 48,125 shares underlying restricted stock units held as of the date of this report. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · balance_after: This total also includes 37,000 shares previously held by The Rachel K. King 2016 GRAT that were transferred to the reporting person on February 25, 2021 and are now owned directly by the reporting person. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 20:58 UTC |
Semerjian HaroutDirector · Chief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 423,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004880 · doc4.xml · derivative · entry 1 Semerjian Harout · CIK 0001809747 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,500 Underlying: Common Stock · 423,500 shares Expires 2032-01-20 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| January 21, 2022 Filed Jan 26, 2022 02:02 UTC |
Girard ArmandSVP, Chief Business Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 47,700 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004896 · doc4.xml · derivative · entry 2 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,700 Underlying: Common Stock · 47,700 shares Expires 2032-01-20 F2 · derivative.exercise_date: 50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 21, 2022 Filed Jan 26, 2022 02:02 UTC |
Girard ArmandSVP, Chief Business Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 144,700 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004896 · doc4.xml · derivative · entry 1 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,700 Underlying: Common Stock · 144,700 shares Expires 2032-01-20 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| January 21, 2022 Filed Jan 26, 2022 02:01 UTC |
Magnani John L.SVP of Research, CSO
|
GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004893 · doc4.xml · derivative · entry 2 Magnani John L. · CIK 0001589713 · SVP of Research, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-20 F2 · derivative.exercise_date: 50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 21, 2022 Filed Jan 26, 2022 02:01 UTC |
Magnani John L.SVP of Research, CSO
|
GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004893 · doc4.xml · derivative · entry 1 Magnani John L. · CIK 0001589713 · SVP of Research, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| January 21, 2022 Filed Jan 26, 2022 01:59 UTC |
Hahn Brian M.SVP Finance, CFO
|
GrantEmployee Stock Option (right to buy) · Derivative | 47,700 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004882 · doc4.xml · derivative · entry 2 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,700 Underlying: Common Stock · 47,700 shares Expires 2032-01-20 F2 · derivative.exercise_date: 50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 21, 2022 Filed Jan 26, 2022 01:59 UTC |
Hahn Brian M.SVP Finance, CFO
|
GrantEmployee Stock Option (right to buy) · Derivative | 164,700 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004882 · doc4.xml · derivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,700 Underlying: Common Stock · 164,700 shares Expires 2032-01-20 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 16:05 UTC |
Andrews Patricia SDirector
|
PurchaseCommon Stock | 40,000 | $2.05 | $82,000.00 |
DisclosureSEC source: 0001209191-21-065434 · doc4.xml · nonDerivative · entry 1 Andrews Patricia S · CIK 0001445710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,250 F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $2.03 to $2.07 per share, with a weighted average purchase price of $2.05 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:58 UTC |
JUNIUS DANIEL MDirector
|
GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-21-036384 · doc4.xml · derivative · entry 2 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-05-17 F3 · derivative.exercise_date: The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:58 UTC |
JUNIUS DANIEL MDirector
|
GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036384 · doc4.xml · nonDerivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 27, 2021 20:54 UTC |
Andrews Patricia SDirector
|
GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-21-036380 · doc4.xml · derivative · entry 2 Andrews Patricia S · CIK 0001445710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-05-17 F3 · derivative.exercise_date: The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 27, 2021 20:54 UTC |
Andrews Patricia SDirector
|
GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036380 · doc4.xml · nonDerivative · entry 1 Andrews Patricia S · CIK 0001445710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:55 UTC |
Jackson Scott ThomasDirector
|
GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-21-036382 · doc4.xml · derivative · entry 2 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-05-17 F3 · derivative.exercise_date: The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:55 UTC |
Jackson Scott ThomasDirector
|
GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036382 · doc4.xml · nonDerivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:51 UTC |
Goldberg Mark AlanDirector
|
GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-21-036378 · doc4.xml · derivative · entry 3 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-05-17 F3 · derivative.exercise_date: The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:51 UTC |
Goldberg Mark AlanDirector
|
GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036378 · doc4.xml · nonDerivative · entry 1 Goldberg Mark Alan · CIK 0001532475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:49 UTC |
Koenig ScottDirector
|
GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-21-036376 · doc4.xml · derivative · entry 2 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-05-17 F3 · derivative.exercise_date: The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:49 UTC |
Koenig ScottDirector
|
GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036376 · doc4.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:47 UTC |
PEARSON TIMOTHY RDirector
|
GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-21-036373 · doc4.xml · derivative · entry 2 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-05-17 F3 · derivative.exercise_date: The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:47 UTC |
PEARSON TIMOTHY RDirector
|
GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036373 · doc4.xml · nonDerivative · entry 1 PEARSON TIMOTHY R · CIK 0001528617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:07 UTC |
Girard ArmandSVP, Chief Business Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001209191-21-004850 · doc4.xml · derivative · entry 2 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-01-19 F3 · derivative.exercise_date: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:07 UTC |
Girard ArmandSVP, Chief Business Officer
|
GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004850 · doc4.xml · nonDerivative · entry 1 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:06 UTC |
Hahn Brian M.SVP Finance, CFO
|
GrantEmployee Stock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001209191-21-004847 · doc4.xml · derivative · entry 2 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2031-01-19 F3 · derivative.exercise_date: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:06 UTC |
Hahn Brian M.SVP Finance, CFO
|
GrantCommon Stock | 34,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004847 · doc4.xml · nonDerivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,760 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:05 UTC |
Thackray Helen M.SVP Clinical Development, CMO
|
GrantEmployee Stock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001209191-21-004845 · doc4.xml · derivative · entry 2 Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2031-01-19 F3 · derivative.exercise_date: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:05 UTC |
Thackray Helen M.SVP Clinical Development, CMO
|
GrantCommon Stock | 34,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004845 · doc4.xml · nonDerivative · entry 1 Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,115 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:03 UTC |
Magnani John L.SVP of Research, CSO
|
GrantEmployee Stock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001209191-21-004840 · doc4.xml · derivative · entry 3 Magnani John L. · CIK 0001589713 · SVP of Research, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2031-01-19 F4 · derivative.exercise_date: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:03 UTC |
Magnani John L.SVP of Research, CSO
|
GrantCommon Stock | 34,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004840 · doc4.xml · nonDerivative · entry 1 Magnani John L. · CIK 0001589713 · SVP of Research, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,260 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:00 UTC |
King Rachel K.Director · President, CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 192,500 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001209191-21-004833 · doc4.xml · derivative · entry 4 King Rachel K. · CIK 0001589712 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,500 Underlying: Common Stock · 192,500 shares Expires 2031-01-19 F4 · derivative.exercise_date: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:00 UTC |
King Rachel K.Director · President, CEO
|
GrantCommon Stock | 96,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004833 · doc4.xml · nonDerivative · entry 1 King Rachel K. · CIK 0001589712 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,314 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 21:00 UTC |
King Rachel K.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 130,821 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-20-065499 · doc4.xml · derivative · entry 5 King Rachel K. · CIK 0001589712 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 130,821 shares Expires 2021-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and subsequent sales were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 4, 2020. F6 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 21:00 UTC |
King Rachel K.Director · President, CEO
|
SaleCommon Stock | 84,176 | $3.91 | $329,128.16 |
DisclosureSEC source: 0001209191-20-065499 · doc4.xml · nonDerivative · entry 2 King Rachel K. · CIK 0001589712 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,064 F1 · kind: This option exercise and subsequent sales were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 4, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $4.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 21:00 UTC |
King Rachel K.Director · President, CEO
|
Exercise / conversionCommon Stock | 130,821 | $1.12 | $146,519.52 |
DisclosureSEC source: 0001209191-20-065499 · doc4.xml · nonDerivative · entry 1 King Rachel K. · CIK 0001589712 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and subsequent sales were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 4, 2020. F2 · balance_after: This total includes 2,275 shares previously held by The Rachel K. King 2016 GRAT that were transferred to the Reporting Person on January 10, 2020 and are now owned directly by the Reporting Person. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:00 UTC |
Hahn Brian M.SVP Finance, CFO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,260 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-20-064018 · doc4.xml · derivative · entry 2 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,260 shares Expires 2021-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:00 UTC |
Hahn Brian M.SVP Finance, CFO
|
Exercise / conversionCommon Stock | 5,260 | $1.12 | $5,891.20 |
DisclosureSEC source: 0001209191-20-064018 · doc4.xml · nonDerivative · entry 1 Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 23:33 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L P10% owner
BVF I GP LLC10% owner
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
BVF II GP LLCSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF GP HOLDINGS LLC10% owner
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 86,090 | $2.60 | $223,834.00 |
DisclosureSEC source: 0000921895-20-002828 · form407422glyc_11062020.xml · nonDerivative · entry 3 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · 10% owner BVF I GP LLC · CIK 0001803805 · 10% owner BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses BVF II GP LLC · CIK 0001803806 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,453 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 23:33 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L P10% owner
BVF I GP LLC10% owner
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
BVF II GP LLCSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF GP HOLDINGS LLC10% owner
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 506,155 | $2.60 | $1,316,003.00 |
DisclosureSEC source: 0000921895-20-002828 · form407422glyc_11062020.xml · nonDerivative · entry 2 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · 10% owner BVF I GP LLC · CIK 0001803805 · 10% owner BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses BVF II GP LLC · CIK 0001803806 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,712,350 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 23:33 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L P10% owner
BVF I GP LLC10% owner
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
BVF II GP LLCSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF GP HOLDINGS LLC10% owner
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 674,492 | $2.60 | $1,753,679.20 |
DisclosureSEC source: 0000921895-20-002828 · form407422glyc_11062020.xml · nonDerivative · entry 1 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · 10% owner BVF I GP LLC · CIK 0001803805 · 10% owner BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses BVF II GP LLC · CIK 0001803806 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,980,812 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 21:44 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BVF I GP LLCSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
BVF II GP LLCSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF GP HOLDINGS LLC10% owner
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 15,472 | $2.75 | $42,548.00 |
DisclosureSEC source: 0000921895-20-002779 · form407422glyc_11032020.xml · nonDerivative · entry 3 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BVF I GP LLC · CIK 0001803805 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses BVF II GP LLC · CIK 0001803806 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,363 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 21:44 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BVF I GP LLCSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
BVF II GP LLCSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF GP HOLDINGS LLC10% owner
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 250,755 | $2.75 | $689,576.25 |
DisclosureSEC source: 0000921895-20-002779 · form407422glyc_11032020.xml · nonDerivative · entry 2 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BVF I GP LLC · CIK 0001803805 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses BVF II GP LLC · CIK 0001803806 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,206,195 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 21:44 UTC |
BVF PARTNERS L P/IL10% owner
BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
BVF I GP LLCSee Explanation of Responses
BIOTECHNOLOGY VALUE FUND II LPSee Explanation of Responses
BVF II GP LLCSee Explanation of Responses
Biotechnology Value Trading Fund OS LPSee Explanation of Responses
BVF Partners OS Ltd.See Explanation of Responses
BVF GP HOLDINGS LLC10% owner
BVF INC/IL10% owner
LAMPERT MARK N10% owner
|
PurchaseCommon Stock, $0.001 par value | 666,385 | $2.75 | $1,832,558.75 |
DisclosureSEC source: 0000921895-20-002779 · form407422glyc_11032020.xml · nonDerivative · entry 1 BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses BVF I GP LLC · CIK 0001803805 · See Explanation of Responses BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses BVF II GP LLC · CIK 0001803806 · See Explanation of Responses Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner BVF INC/IL · CIK 0001056807 · 10% owner LAMPERT MARK N · CIK 0001233840 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,306,320 F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. Read SEC document |
| May 22, 2020 Filed May 27, 2020 20:33 UTC |
JUNIUS DANIEL MDirector
|
GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032315 · doc4.xml · derivative · entry 1 JUNIUS DANIEL M · CIK 0001094159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2030-05-21 F1 · derivative.exercise_date: The shares underlying this option vest on May 22, 2021, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 22, 2020 Filed May 27, 2020 16:27 UTC |
Andrews Patricia SDirector
|
GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032299 · doc4.xml · derivative · entry 1 Andrews Patricia S · CIK 0001445710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2030-05-21 F1 · derivative.exercise_date: The shares underlying this option vest on May 22, 2021, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.